Bill Cherman

About Bill Cherman

Bill is a co-founder of Repair Biotechnologies, a startup developing therapies for thymus regeneration and atherosclerosis reversal, and also a partner at Front Seat Capital, where he leads investments in longevity startups. Previously, he previously worked as a consultant at McKinsey & Company an American worldwide management consulting firm.

Related Organizations

Restoring Heart Regeneration With a Metabolic Switch
In a recent article in Nature, researchers have restored cardiac regeneration to adult mice by disabling fatty acid oxidation, discovering a potential pathway for human treatments. […]
Human Clinical Trials of NMN for Safety and Effectiveness
In a recent paper, researchers reviewed the literature for human clinical trials that address NMN’s safety and anti-aging effects [1]. The roles of NAD+ and NMN in aging NAD+ (nicotinamide adenine dinucleotide) is a molecule essential in […]
Lifespan News – Elon Musk and the Living Forever Curse
On this episode of Lifespan News, Ryan O’Shea ruminates on Elon Musk’s statement on living forever being a curse rather than a blessing. Script Elon Musk has said a lot of stupid stuff about aging and longevity. […]
ARDD 2023: The Mother of All Longevity Conferences
Once a year, Copenhagen becomes a Mecca for the longevity community. Hundreds of people flock to the picturesque Danish capital to attend the Aging Research and Drug Discovery Meeting (ARDD) for five full days […]
An Unexplored Link Between Inflammation and Alzheimer’s
An article in GeroScience describes a previously unexplored relationship between FABP7, an inflammatory molecule that binds to fatty acids, and Alzheimer’s disease. Not just a transporter Originally, as the authors explain, fatty acid binding proteins (FABPs) were […]

Menu

About Bill Cherman

Related Organizations

Register